Drug
Ro7568282
Ro7568282: highest development phase Phase 2, developed by Roche. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| RO7568282 NCT07781644 | Phase 2 | Parkinson's Disease |
| RO7568282 NCT07781657 | Phase 2 | Alzheimer's Disease |
Latest
No recent events.
Follow Ro7568282 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.